Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Hepatitis

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 179 articles:
HTML format



Single Articles


    January 2022
  1. MAWATARI S, Kumagai K, Oda K, Tabu K, et al
    Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus.
    PLoS One. 2022;17:e0262267.
    PubMed     Abstract available


  2. BOODRAM B, Mackesy-Amiti ME, Khanna A, Brickman B, et al
    People who inject drugs in metropolitan Chicago: A meta-analysis of data from 1997-2017 to inform interventions and computational modeling toward hepatitis C microelimination.
    PLoS One. 2022;17:e0248850.
    PubMed     Abstract available


  3. SUZUKI K, Suda G, Yamamoto Y, Abiko S, et al
    Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.
    PLoS One. 2022;17:e0261760.
    PubMed     Abstract available


  4. MBAGA DS, Kenmoe S, Kengne-Nde C, Ebogo-Belobo JT, et al
    Hepatitis B, C and D virus infections and risk of hepatocellular carcinoma in Africa: A meta-analysis including sensitivity analyses for studies comparable for confounders.
    PLoS One. 2022;17:e0262903.
    PubMed     Abstract available


  5. BALIASHVILI D, Averhoff F, Kasradze A, Salyer SJ, et al
    Risk factors and genotype distribution of hepatitis C virus in Georgia: A nationwide population-based survey.
    PLoS One. 2022;17:e0262935.
    PubMed     Abstract available


  6. OCAN M, Acheng F, Otike C, Beinomugisha J, et al
    Antibody levels and protection after Hepatitis B vaccine in adult vaccinated healthcare workers in northern Uganda.
    PLoS One. 2022;17:e0262126.
    PubMed     Abstract available


  7. MORSICA G, Galli L, Messina E, Castagna A, et al
    Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV.
    PLoS One. 2022;17:e0262917.
    PubMed     Abstract available


  8. JOLLY PE, Akinyemiju TF, Sakhuja S, Sheth R, et al
    Association of aflatoxin B1 levels with mean CD4 cell count and uptake of ART among HIV infected patients: A prospective study.
    PLoS One. 2022;17:e0260873.
    PubMed     Abstract available


  9. PRINSENBERG T, Illidge J, Zantkuijl P, Bedert M, et al
    Usability, acceptability, and self-reported impact of an innovative hepatitis C risk reduction intervention for men have sex with men: A mixed methods study.
    PLoS One. 2022;17:e0263654.
    PubMed     Abstract available


  10. LAMORI J, Feng X, Pericone CD, Mesa-Frias M, et al
    Hepatitis vaccination adherence and completion rates and factors associated with low compliance: A claims-based analysis of U.S. adults.
    PLoS One. 2022;17:e0264062.
    PubMed     Abstract available


  11. NAGURA Y, Matsuura K, Iio E, Fujita K, et al
    Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B.
    PLoS One. 2022;17:e0263844.
    PubMed     Abstract available


  12. DESTREMPES F, Gesnik M, Chayer B, Roy-Cardinal MH, et al
    Quantitative ultrasound, elastography, and machine learning for assessment of steatosis, inflammation, and fibrosis in chronic liver disease.
    PLoS One. 2022;17:e0262291.
    PubMed     Abstract available


  13. KHAN M, Khan S, Gondal MF, Bibi S, et al
    Genetic diversity in enhancer II region of HBV genotype D and its association with advanced liver diseases.
    PLoS One. 2022;17:e0261721.
    PubMed     Abstract available


  14. NAGORNYKH AM, Tyumentseva MA, Tyumentsev AI, Akimkin VG, et al
    Protocol for chronic hepatitis B virus infection mouse model development by patient-derived orthotopic xenografts.
    PLoS One. 2022;17:e0264266.
    PubMed     Abstract available


  15. LIM SH, Lee S, Lee YB, Lee CH, et al
    Increased prevalence of transfusion-transmitted diseases among people with tattoos: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0262990.
    PubMed     Abstract available


  16. ANTUAMWINE BB, Herchel ED, Bawa EM
    Comparative prevalence of hepatitis B virus infection among pregnant women accessing free maternal care in a tertiary hospital in Ghana.
    PLoS One. 2022;17:e0263651.
    PubMed     Abstract available


  17. SHRESTHA LB, Yadav GK, Pradhan S, Sharma A, et al
    Co-infection of Hepatitis B and Hepatitis C among HIV-infected patients: A cross-sectional study from tertiary care hospital of eastern Nepal.
    PLoS One. 2022;17:e0264791.
    PubMed     Abstract available


  18. TAHERKHANI R, Farshadpour F
    Prevalence, genotype distribution and mutations of hepatitis B virus and the associated risk factors among pregnant women residing in the northern shores of Persian Gulf, Iran.
    PLoS One. 2022;17:e0265063.
    PubMed     Abstract available


  19. TATARA E, Gutfraind A, Collier NT, Echevarria D, et al
    Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago.
    PLoS One. 2022;17:e0264983.
    PubMed     Abstract available


  20. TRAN L, Jung J, Feldman R, Riley T 3rd, et al
    Disparities in the quality of care for chronic hepatitis C among Medicare beneficiaries.
    PLoS One. 2022;17:e0263913.
    PubMed     Abstract available


  21. TAKAURA K, Kurosaki M, Inada K, Kirino S, et al
    The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy.
    PLoS One. 2022;17:e0264075.
    PubMed     Abstract available


  22. LIN MC, Dai CY, Huang CF, Yeh ML, et al
    Itemization difference of patient-reported outcome in patients with chronic liver disease.
    PLoS One. 2022;17:e0264348.
    PubMed     Abstract available


  23. UCHIDA Y, Nakao M, Yamada S, Tsuji S, et al
    Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog.
    PLoS One. 2022;17:e0262764.
    PubMed     Abstract available


  24. MAGGI P, Calo F, Messina V, Stornaiuolo G, et al
    Cardiovascular disease risk in liver transplant recipients transplanted due to chronic viral hepatitis.
    PLoS One. 2022;17:e0265178.
    PubMed     Abstract available


  25. KIMER N, Meldgaard M, Hamberg O, Kronborg TM, et al
    The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: A randomized clinical trial.
    PLoS One. 2022;17:e0264278.
    PubMed     Abstract available


  26. CHOI SI, Cho Y, Ki M, Kim BH, et al
    Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts.
    PLoS One. 2022;17:e0265668.
    PubMed     Abstract available


  27. REINHARDT B, Taylor R, Dawkins C, Banks T, et al
    The use of dried blood spot cards to assess serologic responses of individuals vaccinated against measles, hepatitis A, tetanus, influenza and varicella zoster.
    PLoS One. 2022;17:e0265813.
    PubMed     Abstract available


  28. YAZDANI K, Dolguikh K, Zhang W, Shayegi-Nik S, et al
    Knowledge of hepatitis C and awareness of reinfection risk among people who successfully completed direct acting antiviral therapy.
    PLoS One. 2022;17:e0265811.
    PubMed     Abstract available


  29. TANA MM, Klepper A, Lyden A, Pisco AO, et al
    Transcriptomic profiling of blood from autoimmune hepatitis patients reveals potential mechanisms with implications for management.
    PLoS One. 2022;17:e0264307.
    PubMed     Abstract available


  30. BURDETTE DL, Lazerwith S, Yang J, Chan HLY, et al
    Ongoing viral replication and production of infectious virus in patients with chronic hepatitis B virus suppressed below the limit of quantitation on long-term nucleos(t)ide therapy.
    PLoS One. 2022;17:e0262516.
    PubMed     Abstract available



  31. Expression of Concern: Interferon and Ribavirin Combination Treatment Synergistically Inhibit HCV Internal Ribosome Entry Site Mediated Translation at the Level of Polyribosome Formation.
    PLoS One. 2022;17:e0266498.
    PubMed    



  32. Expression of Concern: SH2 Modified STAT1 Induces HLA-I Expression and Improves IFN-gamma Signaling in IFN-alpha Resistant HCV Replicon Cells.
    PLoS One. 2022;17:e0266497.
    PubMed    


  33. CHANDRA DEB L, Hove H, Miller TK, Pinks K, et al
    Epidemiology of Hepatitis C virus infection among incarcerated populations in North Dakota.
    PLoS One. 2022;17:e0266047.
    PubMed     Abstract available


  34. XIA Z, Qin L, Ning Z, Zhang X, et al
    Deep learning time series prediction models in surveillance data of hepatitis incidence in China.
    PLoS One. 2022;17:e0265660.
    PubMed     Abstract available


  35. THI CAM HUONG N, Trung NQ, Luong BA, Tram DB, et al
    Mutations in the HBV PreS/S gene related to hepatocellular carcinoma in Vietnamese chronic HBV-infected patients.
    PLoS One. 2022;17:e0266134.
    PubMed     Abstract available


  36. ROJAS ROJAS T, Poizot-Martin I, Rey D, Duvivier C, et al
    Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France.
    PLoS One. 2022;17:e0261069.
    PubMed     Abstract available


  37. SEYOUM E, Demissie M, Worku A, Mulu A, et al
    HIV, hepatitis B virus, and hepatitis C virus co-infection among HIV positives in antiretroviral treatment program in selected hospitals in Addis Ababa: A retrospective cross-sectional study.
    PLoS One. 2022;17:e0267230.
    PubMed     Abstract available


  38. AUMA AWN, Kowal C, Shive CL, Lange A, et al
    Transient elastography score is elevated during rheumatoid factor-positive chronic hepatitis C virus infection and rheumatoid factor decline is highly variable over the course of direct-acting antiviral therapy.
    PLoS One. 2022;17:e0267512.
    PubMed     Abstract available


  39. MABUNDA N, Augusto O, Zicai AF, Duaja A, et al
    Nucleic acid testing identifies high prevalence of blood borne viruses among approved blood donors in Mozambique.
    PLoS One. 2022;17:e0267472.
    PubMed     Abstract available


  40. FACENTE SN, Grinstein R, Bruhn R, Kaidarova Z, et al
    Hepatitis C prevalence and key population size estimate updates in San Francisco: 2015 to 2019.
    PLoS One. 2022;17:e0267902.
    PubMed     Abstract available


  41. MANZOOR S, Khalid M, Idrees M
    P2X4 receptors mediate induction of antioxidants, fibrogenic cytokines and ECM transcripts; in presence of replicating HCV in in vitro setting: An insight into role of P2X4 in fibrosis.
    PLoS One. 2022;17:e0259727.
    PubMed     Abstract available


  42. SSEKAMATTE T, Isunju JB, Mutyoba JN, Tetui M, et al
    Predictors of Hepatitis B screening and vaccination status of young psychoactive substance users in informal settlements in Kampala, Uganda.
    PLoS One. 2022;17:e0267953.
    PubMed     Abstract available


  43. GUZMAN-HOLST A, Luna-Casas G, Burguete Garcia A, Madrid-Marina V, et al
    Burden of disease and associated complications of hepatitis a in children and adults in Mexico: A retrospective database study.
    PLoS One. 2022;17:e0268469.
    PubMed     Abstract available


  44. BATSAIKHAN B, Huang CI, Yeh ML, Huang CF, et al
    Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients.
    PLoS One. 2022;17:e0268180.
    PubMed     Abstract available


  45. O'DONNELL A, Pham N, Battisti L, Epstein R, et al
    Estimating the causal effect of treatment with direct-acting antivirals on kidney function among individuals with hepatitis C virus infection.
    PLoS One. 2022;17:e0268478.
    PubMed     Abstract available


  46. MARQUEZ LK, Ingiliz P, Boesecke C, Krznaric I, et al
    Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysis.
    PLoS One. 2022;17:e0267853.
    PubMed     Abstract available


  47. ULLAH A, Yu X, Odenthal M, Meemboor S, et al
    Circulating microRNA-122 in HCV cirrhotic patients with high frequency of genotype 3.
    PLoS One. 2022;17:e0268526.
    PubMed     Abstract available


  48. BOFF DA COSTA R, Boff Costa M, Longo L, Miotto DE, et al
    Correction: Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications.
    PLoS One. 2022;17:e0269049.
    PubMed     Abstract available


  49. FERNANDEZ VILLALOBOS NV, Kessel B, Rodiah I, Ott JJ, et al
    Seroprevalence of hepatitis E virus infection in the Americas: Estimates from a systematic review and meta-analysis.
    PLoS One. 2022;17:e0269253.
    PubMed     Abstract available


  50. KENFACK-MOMO R, Kenmoe S, Takuissu GR, Ebogo-Belobo JT, et al
    Epidemiology of hepatitis B virus and/or hepatitis C virus infections among people living with human immunodeficiency virus in Africa: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0269250.
    PubMed     Abstract available


  51. DIAMOND T, Burn TN, Nishiguchi MA, Minichino D, et al
    Familial hemophagocytic lymphohistiocytosis hepatitis is mediated by IFN-gamma in a predominantly hepatic-intrinsic manner.
    PLoS One. 2022;17:e0269553.
    PubMed     Abstract available


  52. CHUAYPEN N, Siripongsakun S, Hiranrat P, Tanpowpong N, et al
    Improvement of liver fibrosis, but not steatosis, after HCV eradication as assessment by MR-based imaging: Role of metabolic derangement and host genetic variants.
    PLoS One. 2022;17:e0269641.
    PubMed     Abstract available


  53. MADEIRA F, Costa-Lopes R, Do Bu EA, Tato Marinho R, et al
    The role of stereotypical information on medical judgements for black and white patients.
    PLoS One. 2022;17:e0268888.
    PubMed     Abstract available


  54. SIEDLECKA M, Kublicka A, Wieliczko A, Matczuk AK, et al
    Molecular detection of avian hepatitis E virus (Orthohepevirus B) in chickens, ducks, geese, and western capercaillies in Poland.
    PLoS One. 2022;17:e0269854.
    PubMed     Abstract available


  55. ISUNJU JB, Wafula ST, Ndejjo R, Nuwematsiko R, et al
    Awareness of hepatitis B post-exposure prophylaxis among healthcare providers in Wakiso district, Central Uganda.
    PLoS One. 2022;17:e0270181.
    PubMed     Abstract available


  56. RAU M, Buggisch P, Mauss S, Boeker KHW, et al
    Prognostic impact of steatosis in the clinical course of chronic HCV infection-Results from the German Hepatitis C-Registry.
    PLoS One. 2022;17:e0264741.
    PubMed     Abstract available


  57. SONO S, Sae-Chan J, Kaewdech A, Chamroonkul N, et al
    HBV seroprevalence and liver fibrosis status among population born before national immunization in Southern Thailand: Findings from a health check-up program.
    PLoS One. 2022;17:e0270458.
    PubMed     Abstract available


  58. CHEN YC, Wang HW, Huang YT, Jiang MY, et al
    Association of hepatitis C virus infection status and genotype with kidney disease risk: A population-based cross-sectional study.
    PLoS One. 2022;17:e0271197.
    PubMed     Abstract available


  59. CAIROLI V, De Matteo E, Casciato P, Ameigeiras B, et al
    The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects.
    PLoS One. 2022;17:e0270911.
    PubMed     Abstract available


  60. SHIRAI K, Hikita H, Sakane S, Narumi R, et al
    Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients.
    PLoS One. 2022;17:e0271020.
    PubMed     Abstract available


  61. WOO HY, Heo J, Tak WY, Lee HJ, et al
    Effect of switching from nucleos(t)ide maintenance therapy to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomized trial.
    PLoS One. 2022;17:e0270716.
    PubMed     Abstract available


  62. WANG CH, Lin RC, Hsu HY, Tseng YT, et al
    Hormone replacement therapy is associated with reduced hepatocellular carcinoma risk and improved survival in postmenopausal women with hepatitis B: A nationwide long-term population-based cohort study.
    PLoS One. 2022;17:e0271790.
    PubMed     Abstract available


  63. SAHIBZADA KI, Ganova-Raeva L, Dimitrova Z, Ramachandran S, et al
    Hepatitis C virus transmission cluster among injection drug users in Pakistan.
    PLoS One. 2022;17:e0270910.
    PubMed     Abstract available


  64. MATA-MARIN JA, de Pablos-Leal AA, Mauss S, Arroyo-Anduiza CI, et al
    Risk factors for HCV transmission in HIV-positive men who have sex with men in Mexico.
    PLoS One. 2022;17:e0269977.
    PubMed     Abstract available


  65. WAHOME PK, Kiende P, Nakazea RJ, Mwasowa NM, et al
    Occult hepatitis B virus infections and risk factors among school-going adolescent voluntary blood donors in Kwale County Kenya, January 2020-June 2021: Cross sectional study.
    PLoS One. 2022;17:e0263473.
    PubMed     Abstract available


  66. LAHOOD A, Rahman R, McKenna L, Frick M, et al
    Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different.
    PLoS One. 2022;17:e0271102.
    PubMed     Abstract available


  67. PISANO MB, Campbell C, Anugwom C, Re VE, et al
    Hepatitis E virus infection in the United States: Seroprevalence, risk factors and the influence of immunological assays.
    PLoS One. 2022;17:e0272809.
    PubMed     Abstract available


  68. VAKILI J, Sizemore L, Rebeiro PF, Tyndall B, et al
    Assessment of Tennessee's county-level vulnerability to hepatitis C virus and HIV outbreaks using socioeconomic, healthcare, and substance use indicators.
    PLoS One. 2022;17:e0270891.
    PubMed     Abstract available


  69. HYRINA A, Burdette D, Song Z, Ramirez R, et al
    Targeting lipid biosynthesis pathways for hepatitis B virus cure.
    PLoS One. 2022;17:e0270273.
    PubMed     Abstract available


  70. SCHORR O, Blach S, Thurnheer C, Ruis C, et al
    Modelling the microelimination of chronic hepatitis C in the canton of Bern, Switzerland: Reaching the Swiss Hepatitis Strategy goals despite the impact of the COVID 19 pandemic.
    PLoS One. 2022;17:e0272518.
    PubMed     Abstract available


  71. LU YH, Lu CK, Chen CH, Hsieh YY, et al
    Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting.
    PLoS One. 2022;17:e0272567.
    PubMed     Abstract available


  72. TESFU MA, Belay NB, Habtemariam TT
    Co-infection of HIV or HCV among HBsAg positive delivering mothers and its associated factors in governmental hospitals in Addis Ababa, Ethiopia: A cross-sectional study.
    PLoS One. 2022;17:e0273300.
    PubMed     Abstract available


  73. STOPKA TJ, Yaghi O, Li M, Paintsil E, et al
    Molecular and spatial epidemiology of HCV among people who inject drugs in Boston, Massachusetts.
    PLoS One. 2022;17:e0266216.
    PubMed     Abstract available


  74. KHALID FK, Rasheed NA, Hussein NR, Naqid IA, et al
    A study of HBV infection and its risk factors in pregnant women in Zakho city, Iraq.
    PLoS One. 2022;17:e0273362.
    PubMed     Abstract available


  75. TAKUISSU GR, Kenmoe S, Amougou Atsama M, Atenguena Okobalemba E, et al
    Global epidemiology of occult hepatitis B virus infections in blood donors, a systematic review and meta-analysis.
    PLoS One. 2022;17:e0272920.
    PubMed     Abstract available


  76. CELESTE-VILLALVIR A, Wilkerson JM, Markham C, Rodriguez L, et al
    A qualitative investigation of organizational challenges and facilitators to screening individuals experiencing homelessness for hepatitis C virus (HCV) in Houston, Texas.
    PLoS One. 2022;17:e0273302.
    PubMed     Abstract available


  77. BEHMARD E, Abdulabbas HT, Abdalkareem Jasim S, Najafipour S, et al
    Design of a novel multi-epitope vaccine candidate against hepatitis C virus using structural and nonstructural proteins: An immunoinformatics approach.
    PLoS One. 2022;17:e0272582.
    PubMed     Abstract available


  78. NARTEY YA, Antwi SO, Bockarie AS, Hiebert L, et al
    Mortality burden due to liver cirrhosis and hepatocellular carcinoma in Ghana; prevalence of risk factors and predictors of poor in-hospital survival.
    PLoS One. 2022;17:e0274544.
    PubMed     Abstract available


  79. KACEM M, Dhouib W, Bennasrallah C, Zemni I, et al
    Occupational exposure to hepatitis C virus infection and associated factors among healthcare workers in Fattouma Bourguiba University Hospital, Tunisia.
    PLoS One. 2022;17:e0274609.
    PubMed     Abstract available


  80. YOKOKAWA H, Shinohara M, Teraoka Y, Imamura M, et al
    Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants.
    PLoS One. 2022;17:e0274283.
    PubMed     Abstract available


  81. WANG P, Zhang L, He J, Zhang G, et al
    Accuracy of hepatitis B disease surveillance, Gannan prefecture, Gansu province, China; 2017.
    PLoS One. 2022;17:e0274798.
    PubMed     Abstract available


  82. HEREDIA JE, Sorenson C, Flanagan S, Nunez V, et al
    IL-23 signaling is not an important driver of liver inflammation and fibrosis in murine non-alcoholic steatohepatitis models.
    PLoS One. 2022;17:e0274582.
    PubMed     Abstract available


  83. LEE AW, Jacobs W, Tran M, Nguyen B, et al
    Sociodemographic characteristics associated with hepatitis C virus infection in Vietnamese Americans: A cross-sectional analysis of community screening data.
    PLoS One. 2022;17:e0275210.
    PubMed     Abstract available


  84. MABUNDA N, Vieira L, Chelene I, Maueia C, et al
    Prevalence of hepatitis B virus and immunity status among healthcare workers in Beira City, Mozambique.
    PLoS One. 2022;17:e0276283.
    PubMed     Abstract available


  85. IBRAHIM ST, Abdelhamid MR, Lewis N, Baddour N, et al
    Role of fluid-phase complement system regulation in the development of hepatitis C virus-associated glomerulonephritis.
    PLoS One. 2022;17:e0276017.
    PubMed     Abstract available


  86. EL SHEREF SEDM, Afify S, Berengy MS
    Clinical characteristics and predictors of esophagogastric variceal bleeding among patients with HCV-induced liver cirrhosis: An observational comparative study.
    PLoS One. 2022;17:e0275373.
    PubMed     Abstract available


  87. BADSHAH Y, Shabbir M, Khan K, Fatima M, et al
    Manipulation of Interleukin-6 (IL-6) and Transforming Growth Factor Beta-1(TGFbeta-1) towards viral induced liver cancer pathogenesis.
    PLoS One. 2022;17:e0275834.
    PubMed     Abstract available


  88. YAMATAKA K, Chu PS, Koda Y, Taniki N, et al
    Dynamics of type IV collagen 7S fragment on eradication of HCV with direct antiviral agents: Prognostic and metabolomic impacts.
    PLoS One. 2022;17:e0276925.
    PubMed     Abstract available


  89. CHIA CT, Bender AT, Lillis L, Sullivan BP, et al
    Rapid detection of hepatitis C virus using recombinase polymerase amplification.
    PLoS One. 2022;17:e0276582.
    PubMed     Abstract available


  90. OTHMAN B, Barakat M, Omar A, Al-Rawashdeh A, et al
    Evaluation of hepatitis B knowledge, practices, and beliefs among the Jordanian population: A cross-sectional study.
    PLoS One. 2022;17:e0277186.
    PubMed     Abstract available


  91. YEE LM, Shah SK, Grobman WA, Labellarte PZ, et al
    Identifying barriers and facilitators of the inclusion of pregnant individuals in hepatitis C treatment programs in the United States.
    PLoS One. 2022;17:e0277987.
    PubMed     Abstract available


  92. PRONIER C, Bomo J, Besombes J, Genet V, et al
    Characterization of hepatitis B viral forms from patient plasma using velocity gradient: Evidence for an excess of capsids in fractions enriched in Dane particles.
    PLoS One. 2022;17:e0272474.
    PubMed     Abstract available


  93. DAGNEW M, Moges F, Tiruneh M, Million Y, et al
    Molecular diversity of hepatitis B virus among pregnant women in Amhara National Regional State, Ethiopia.
    PLoS One. 2022;17:e0276687.
    PubMed     Abstract available


  94. ABU EL-MAKAREM MA, Kamel MF, Mohamed AA, Ali HA, et al
    Down-regulation of hepatic expression of GHR/STAT5/IGF-1 signaling pathway fosters development and aggressiveness of HCV-related hepatocellular carcinoma: Crosstalk with Snail-1 and type 2 transforming growth factor-beta receptor.
    PLoS One. 2022;17:e0277266.
    PubMed     Abstract available


  95. DABROWSKA-LEONIK N, Sawicka-Powierza J, Bernatowska E, Pac M, et al
    Lack of relationship between 25-hydoxyvitamin D concentration and a titer of antibodies to hepatitis B surface antigen in children under 12 years of age.
    PLoS One. 2022;17:e0277473.
    PubMed     Abstract available


  96. NAGUIB M, Abdel-Razek W, Estaphan S, Abdelsameea E, et al
    Impact of prothrombin and factor V Leiden mutations on the progression of fibrosis in patients with chronic hepatitis C.
    PLoS One. 2022;17:e0276592.
    PubMed     Abstract available


    January 2021
  97. TONEN-WOLYEC S, Djang'eing'a RM, Batina-Agasa S, Kayembe Tshilumba C, et al
    Self-testing for HIV, HBV, and HCV using finger-stick whole-blood multiplex immunochromatographic rapid test: A pilot feasibility study in sub-Saharan Africa.
    PLoS One. 2021;16:e0249701.
    PubMed     Abstract available



  98. Correction: Seroepidemiology of hepatitis A, B, C, D and E virus infections in the general population of Peru: A cross-sectional study.
    PLoS One. 2021;16:e0250185.
    PubMed     Abstract available


  99. MIRZAZADEH A, Chen YH, Lin J, Burk K, et al
    Progress toward closing gaps in the hepatitis C virus cascade of care for people who inject drugs in San Francisco.
    PLoS One. 2021;16:e0249585.
    PubMed     Abstract available


  100. KASHIWAKURA JI, Saitoh K, Ihara T, Sasaki Y, et al
    Correction: Expression of signal-transducing adaptor protein-1 attenuates experimental autoimmune hepatitis via down-regulating activation and homeostasis of invariant natural killer T cells.
    PLoS One. 2021;16:e0250536.
    PubMed     Abstract available


  101. AHMED HR, Waly NGFM, Abd El-Baky RM, Yahia R, et al
    Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C.
    PLoS One. 2021;16:e0249770.
    PubMed     Abstract available


  102. PONNUVEL S, Fletcher GJ, Anantharam R, Varughese S, et al
    Clinical utility of hepatitis C virus core antigen (HCVcAg) assay to identify active HCV infection in hemodialysis and renal transplant patients.
    PLoS One. 2021;16:e0250263.
    PubMed     Abstract available


  103. PALAYEW A, Schmidt AM, Saeed S, Cooper CL, et al
    Estimating an individual-level deprivation index for HIV/HCV coinfected persons in Canada.
    PLoS One. 2021;16:e0249836.
    PubMed     Abstract available


  104. ANTENEH ZA, Wondaye E, Mengesha EW
    Hepatitis B virus infection and its determinants among HIV positive pregnant women: Multicenter unmatched case-control study.
    PLoS One. 2021;16:e0251084.
    PubMed     Abstract available


  105. VIEIRA BARBOSA J, Sahli R, Aubert V, Chaouch A, et al
    Demographics and outcomes of hepatitis B and D: A 10-year retrospective analysis in a Swiss tertiary referral center.
    PLoS One. 2021;16:e0250347.
    PubMed     Abstract available


  106. KAARTINEN K, Vuoti S, Honkanen E, Loyttyniemi E, et al
    Tubular cell damage may be the earliest sign of renal extrahepatic manifestation caused by Hepatitis C.
    PLoS One. 2021;16:e0251392.
    PubMed     Abstract available



  107. Correction: Correction: Seroepidemiology of hepatitis A, B, C, D and E virus infections in the general population of Peru: A cross-sectional study.
    PLoS One. 2021;16:e0251539.
    PubMed     Abstract available


  108. LEE CY, Wu PH, Lu MW, Chen TC, et al
    High prevalence of unawareness of HCV infection status among both HCV-seronegative and seropositive people living with human immunodeficiency virus in Taiwan.
    PLoS One. 2021;16:e0251158.
    PubMed     Abstract available


  109. BUGGISCH P, Heiken H, Mauss S, Weber B, et al
    Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study.
    PLoS One. 2021;16:e0250833.
    PubMed     Abstract available


  110. CHA HJ, Hwang J, Lee LE, Park Y, et al
    The significance of cytoplasmic antinuclear antibody patterns in autoimmune liver disease.
    PLoS One. 2021;16:e0244950.
    PubMed     Abstract available


  111. IREKEOLA AA, Malek NA, Wada Y, Mustaffa N, et al
    Prevalence of HCV genotypes and subtypes in Southeast Asia: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0251673.
    PubMed     Abstract available


  112. BOBARDT M, Ramirez CM, Baum MM, Ure D, et al
    The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance.
    PLoS One. 2021;16:e0251934.
    PubMed     Abstract available


  113. DIDIYA R, Gyenwali D, Pokhrel TN, Devkota S, et al
    Community led testing among people who inject drugs: A community centered model to find new cases of HIV and Hepatitis C in Nepal.
    PLoS One. 2021;16:e0252490.
    PubMed     Abstract available


  114. MALAMBA SS, Muyinda H, Ogwang DM, Katamba A, et al
    Cango Lyec (Healing the Elephant): Chronic Hepatitis B Virus among post-conflict affected populations living in mid-Northern Uganda.
    PLoS One. 2021;16:e0251573.
    PubMed     Abstract available


  115. WURCEL AG, Reyes J, Zubiago J, Koutoujian PJ, et al
    "I'm not gonna be able to do anything about it, then what's the point?": A broad group of stakeholders identify barriers and facilitators to HCV testing in a Massachusetts jail.
    PLoS One. 2021;16:e0250901.
    PubMed     Abstract available


  116. PARK JS, Wong J, Cohen H
    Hepatitis C virus screening of high-risk patients in a community hospital emergency department: Retrospective review of patient characteristics and future implications.
    PLoS One. 2021;16:e0252976.
    PubMed     Abstract available


  117. WYNN A, Tweeten S, McDonald E, Wooten W, et al
    The estimated hepatitis C seroprevalence and key population sizes in San Diego in 2018.
    PLoS One. 2021;16:e0251635.
    PubMed     Abstract available


  118. FLEISHER I, Geboy AG, Nichols W, Desale S, et al
    HIV testing in patients who are HCV positive: Compliance with CDC guidelines in a large healthcare system.
    PLoS One. 2021;16:e0252412.
    PubMed     Abstract available


  119. GAHRTON C, Hakansson A, Kaberg M, Jerkeman A, et al
    Mortality among amphetamine users with hepatitis C virus infection: A nationwide study.
    PLoS One. 2021;16:e0253710.
    PubMed     Abstract available


  120. RASTOGI A, Chauhan S, Ramalingam A, Verma M, et al
    Capacity building of healthcare workers: Key step towards elimination of viral hepatitis in developing countries.
    PLoS One. 2021;16:e0253539.
    PubMed     Abstract available


  121. TORO DM, Ramasawmy R, Silva Neto PV, Pereira GL, et al
    Inflammasome genes polymorphisms may influence the development of hepatitis C in the Amazonas, Brazil.
    PLoS One. 2021;16:e0253470.
    PubMed     Abstract available


  122. RAHMAN S, Wathington D, Waterboer T, Pawlita M, et al
    Seroprevalence of Chlamydia trachomatis, herpes simplex 2, Epstein-Barr virus, hepatitis C and associated factors among a cohort of men ages 18-70 years from three countries.
    PLoS One. 2021;16:e0253005.
    PubMed     Abstract available


  123. ADANE T, Getawa S
    The prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0251570.
    PubMed     Abstract available


  124. LIU HY, Lin YH, Lin PJ, Tsai PC, et al
    Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection.
    PLoS One. 2021;16:e0254028.
    PubMed     Abstract available


  125. GOMES LC, Sanson MCG, Brainin P, de Melo MDCV, et al
    Levels of hepatitis B antibody titers are affected by age and doses gap time in children from a high endemic area of the western Amazon.
    PLoS One. 2021;16:e0253752.
    PubMed     Abstract available


  126. LLORENS-REVULL M, Costafreda MI, Rico A, Guerrero-Murillo M, et al
    Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy.
    PLoS One. 2021;16:e0254243.
    PubMed     Abstract available


  127. HOA TN, Munshi SU, Ngoc KN, Ngoc CL, et al
    A tightly clustered hepatitis E virus genotype 1a is associated with endemic and outbreak infections in Bangladesh.
    PLoS One. 2021;16:e0255054.
    PubMed     Abstract available


  128. BLOOM DE, Khoury A, Srinivasan V
    Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.
    PLoS One. 2021;16:e0252764.
    PubMed     Abstract available


  129. PRENTOE J, Janitzek CM, Velazquez-Moctezuma R, Goksoyr L, et al
    Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens.
    PLoS One. 2021;16:e0255336.
    PubMed     Abstract available


  130. DEFANTE FERRETO LE, Guedes S, Braz Pauli F, Soligo Rovani S, et al
    Seroprevalence and associated factors of HIV and Hepatitis C in Brazilian high-security prisons: A state-wide epidemiological study.
    PLoS One. 2021;16:e0255173.
    PubMed     Abstract available


  131. JOSHUA PE, Nwauzor CO, Odimegwu DC, Ukachukwu UG, et al
    Experimental and molecular predictions of the adjuvanticity of snail mucin on hepatitis B vaccine in albino mice.
    PLoS One. 2021;16:e0246915.
    PubMed     Abstract available


  132. RUTHERFORD L, Stark A, Ablona A, Klassen BJ, et al
    Health and well-being of trans and non-binary participants in a community-based survey of gay, bisexual, and queer men, and non-binary and Two-Spirit people across Canada.
    PLoS One. 2021;16:e0246525.
    PubMed     Abstract available


  133. ERIKSEN LL, Nielsen MA, Laursen TL, Deleuran B, et al
    Early loss of T lymphocyte 4-1BB receptor expression is associated with higher short-term mortality in alcoholic hepatitis.
    PLoS One. 2021;16:e0255574.
    PubMed     Abstract available


  134. SINN DH, Kang D, Hong YS, Koh KC, et al
    Prior antiviral treatment and mortality among patients with hepatitis C virus-related hepatocellular carcinoma: A national cohort study.
    PLoS One. 2021;16:e0255624.
    PubMed     Abstract available


  135. YUNIHASTUTI E, Hariyanto R, Sulaiman AS, Harimurti K, et al
    Hepatitis C continuum of care: Experience of integrative hepatitis C treatment within a human immunodeficiency virus clinic in Indonesia.
    PLoS One. 2021;16:e0256164.
    PubMed     Abstract available


  136. ISRAR M, Ali F, Nawaz A, Idrees M, et al
    Seroepidemiology and associated risk factors of hepatitis B and C virus infections among pregnant women attending maternity wards at two hospitals in Swabi, Khyber Pakhtunkhwa, Pakistan.
    PLoS One. 2021;16:e0255189.
    PubMed     Abstract available


  137. AHSAN A, Dar S, Hassan F, Ghafoor F, et al
    Characterization of linear epitope specificity of antibodies potentially contributing to spontaneous clearance of hepatitis C virus.
    PLoS One. 2021;16:e0256816.
    PubMed     Abstract available


  138. HEFZY EM, Hassuna NA, Shaker OG, Masoud M, et al
    miR-155 T/A (rs767649) and miR-146a A/G (rs57095329) single nucleotide polymorphisms as risk factors for chronic hepatitis B virus infection among Egyptian patients.
    PLoS One. 2021;16:e0256724.
    PubMed     Abstract available


  139. KOBAYASHI H, Joshita S, Akahane Y, Matsuzaki K, et al
    Protocol: Prospective observational study aiming for micro-elimination of hepatitis C virus in Nagawa town: The Nagawa Project.
    PLoS One. 2021;16:e0256711.
    PubMed     Abstract available


  140. CHEN YC, Li CH, Ko PH, Lee CC, et al
    Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals.
    PLoS One. 2021;16:e0256505.
    PubMed     Abstract available


  141. OSAMUDIAMEN FT, Akanbi OA, Oluwayelu DO, Bock CT, et al
    Serological evidence of avian HEV antibodies in apparently healthy chickens in southwest Nigeria.
    PLoS One. 2021;16:e0247889.
    PubMed     Abstract available


  142. ATSUKAWA M, Tsubota A, Kondo C, Uchida-Kobayashi S, et al
    A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C.
    PLoS One. 2021;16:e0257166.
    PubMed     Abstract available


  143. GHOSH A, Onsager C, Mason A, Arriola L, et al
    The role of oxygen intake and liver enzyme on the dynamics of damaged hepatocytes: Implications to ischaemic liver injury via a mathematical model.
    PLoS One. 2021;16:e0230833.
    PubMed     Abstract available


  144. HAILE K, Timerga A, Mose A, Mekonnen Z, et al
    Hepatitis B vaccination status and associated factors among students of medicine and health sciences in Wolkite University, Southwest Ethiopia: A cross-sectional study.
    PLoS One. 2021;16:e0257621.
    PubMed     Abstract available


  145. QUAYE T, Narkwa PW, Domfeh SA, Kattah G, et al
    Immunosurveillance and molecular detection of hepatitis B virus infection amongst vaccinated children in the West Gonja District in Savanna Region of Ghana.
    PLoS One. 2021;16:e0257103.
    PubMed     Abstract available


  146. KWON JA, Dore GJ, Hajarizadeh B, Alavi M, et al
    Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications.
    PLoS One. 2021;16:e0257369.
    PubMed     Abstract available


  147. MIZUNO K, Haga H, Okumoto K, Hoshikawa K, et al
    Intrahepatic distribution of nerve fibers and alterations due to fibrosis in diseased liver.
    PLoS One. 2021;16:e0249556.
    PubMed     Abstract available


  148. KONG L, Karns R, Shata MTM, Brown JL, et al
    The synthetic opioid fentanyl enhances viral replication in vitro.
    PLoS One. 2021;16:e0249581.
    PubMed     Abstract available


  149. WAKABAYASHI SI, Joshita S, Kimura K, Motoki H, et al
    Protocol: Prospective observational study investigating the prevalence and clinical outcome of portopulmonary hypertension in Japanese patients with chronic liver disease.
    PLoS One. 2021;16:e0249435.
    PubMed     Abstract available


  150. LEE SO, Lee JE, Lee S, Lee SH, et al
    Prevalence and patterns of illicit drug use in people with human immunodeficiency virus infection in Korea.
    PLoS One. 2021;16:e0249361.
    PubMed     Abstract available


  151. MAZHAR MKA, Finger F, Evers ES, Kuehne A, et al
    An outbreak of acute jaundice syndrome (AJS) among the Rohingya refugees in Cox's Bazar, Bangladesh: Findings from enhanced epidemiological surveillance.
    PLoS One. 2021;16:e0250505.
    PubMed     Abstract available


  152. AFANEH H, Straif-Bourgeois S, Oral E, Wennerstrom A, et al
    Louisiana Medicaid access for treatment and care for hepatitis C virus (LA-MATCH) project: A cross-sectional study protocol.
    PLoS One. 2021;16:e0257437.
    PubMed     Abstract available


  153. KANG SH, Cho DH, Choi J, Baik SK, et al
    Association between chronic hepatitis B infection and COVID-19 outcomes: A Korean nationwide cohort study.
    PLoS One. 2021;16:e0258229.
    PubMed     Abstract available


  154. SAINE ME, Szymczak JE, Moore TM, Bamford LP, et al
    The impact of disease-related knowledge on perceptions of stigma among patients with Hepatitis C Virus (HCV) infection.
    PLoS One. 2021;16:e0258143.
    PubMed     Abstract available


  155. BALEGHA AN, Yidana A, Abiiro GA
    Knowledge, attitude and practice of hepatitis B infection prevention among nursing students in the Upper West Region of Ghana: A cross-sectional study.
    PLoS One. 2021;16:e0258757.
    PubMed     Abstract available


  156. ELKARANSHAWY HA, Ezzat HM, Ibrahim NN
    Lyapunov function and global asymptotic stability for a new multiscale viral dynamics model incorporating the immune system response: Implemented upon HCV.
    PLoS One. 2021;16:e0257975.
    PubMed     Abstract available


  157. KAMALI I, Barnhart DA, Ndahimana JD, Noor K, et al
    Prevalence and associated risk factors for hepatitis B and C viruses among refugee populations living in Mahama, Rwanda: A cross-sectional study.
    PLoS One. 2021;16:e0257917.
    PubMed     Abstract available


  158. PEDARRIEU A, El Mellouli F, Khallouki H, Zro K, et al
    External quality assessment of Rift Valley fever diagnosis in countries at risk of the disease: African, Indian Ocean and Middle-East regions.
    PLoS One. 2021;16:e0251263.
    PubMed     Abstract available


  159. MREMI A, Yahaya JJ, Nyindo M, Mollel E, et al
    Transfusion-Transmitted Infections and associated risk factors at the Northern Zone Blood Transfusion Center in Tanzania: A study of blood donors between 2017 and 2019.
    PLoS One. 2021;16:e0249061.
    PubMed     Abstract available


  160. OLAKUNDE BO, Adeyinka DA, Olakunde OA, Uthman OA, et al
    A systematic review and meta-analysis of the prevalence of hepatitis B virus infection among pregnant women in Nigeria.
    PLoS One. 2021;16:e0259218.
    PubMed     Abstract available


  161. KLOK S, van Dulm E, Boyd A, Generaal E, et al
    Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections among undocumented migrants and uninsured legal residents in the Netherlands: A cross-sectional study, 2018-2019.
    PLoS One. 2021;16:e0258932.
    PubMed     Abstract available


  162. PAN CQ, Chang TT, Bae SH, Brunetto M, et al
    Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV.
    PLoS One. 2021;16:e0251552.
    PubMed     Abstract available


  163. FERRETO LED, Guedes SJKO, Pauli FB, Rovani SS, et al
    Correction: Seroprevalence and associated factors of HIV and Hepatitis C in Brazilian high-security prisons: A state-wide epidemiological study.
    PLoS One. 2021;16:e0260179.
    PubMed     Abstract available


  164. STEPHENS Z, O'Brien D, Dehankar M, Roberts LR, et al
    Exogene: A performant workflow for detecting viral integrations from paired-end next-generation sequencing data.
    PLoS One. 2021;16:e0250915.
    PubMed     Abstract available


  165. DUAH A, Agyei-Nkansah A, Osei-Poku F, Duah F, et al
    Sociodemographic characteristics, complications requiring hospital admission and causes of in-hospital death in patients with liver cirrhosis admitted at a district hospital in Ghana.
    PLoS One. 2021;16:e0253759.
    PubMed     Abstract available


  166. CASTRO LS, Rezende GR, Pires Fernandes FR, Bandeira LM, et al
    HAV infection in Brazilian men who have sex with men: The importance of surveillance to avoid outbreaks.
    PLoS One. 2021;16:e0256818.
    PubMed     Abstract available


  167. TOWNSHEND-BULSON L, Roik E, Barbour Y, Bruden DJT, et al
    The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals.
    PLoS One. 2021;16:e0260970.
    PubMed     Abstract available


  168. YU S, Chen W, Jiang Z
    Platelet count/spleen volume ratio has a good predictive value for esophageal varices in patients with hepatitis B liver cirrhosis.
    PLoS One. 2021;16:e0260774.
    PubMed     Abstract available


  169. HERNANDEZ-SUAREZ G, Saha D, Lodrono K, Boonmahittisut P, et al
    Seroprevalence and incidence of hepatitis A in Southeast Asia: A systematic review.
    PLoS One. 2021;16:e0258659.
    PubMed     Abstract available


  170. GUAN TH, Htut HN, Davison CM, Sebastian S, et al
    Implementation of a neonatal hepatitis B immunization program in rural Karenni State, Myanmar: A mixed-methods study.
    PLoS One. 2021;16:e0261470.
    PubMed     Abstract available


  171. GARCIA-HEROLA A, Dominguez-Hernandez R, Casado MA
    Clinical and economic impact of an alert system in primary care for the detection of patients with chronic hepatitis C.
    PLoS One. 2021;16:e0260608.
    PubMed     Abstract available


  172. ABGHOUR S, Mouahid M, Darkaoui S, Berrada J, et al
    Pathogenicity of field strain of fowl aviadenovirus serotype 11 isolated from chickens with inclusion body hepatitis in Morocco.
    PLoS One. 2021;16:e0261284.
    PubMed     Abstract available


  173. NERSESOV A, Gusmanov A, Crape B, Junusbekova G, et al
    Seroprevalence and risk factors for hepatitis B and hepatitis C in three large regions of Kazakhstan.
    PLoS One. 2021;16:e0261155.
    PubMed     Abstract available


  174. BITTY-ANDERSON AM, Ferre V, Gbeasor-Komlanvi FA, Tchankoni MK, et al
    Prevalence of hepatitis B and C among female sex workers in Togo, West Africa.
    PLoS One. 2021;16:e0259891.
    PubMed     Abstract available


  175. DE VOS CJ, Hennen WHGJ, van Roermund HJW, Dhollander S, et al
    Assessing the introduction risk of vector-borne animal diseases for the Netherlands using MINTRISK: A Model for INTegrated RISK assessment.
    PLoS One. 2021;16:e0259466.
    PubMed     Abstract available


  176. SUZUKI T, Matsuura K, Nagura Y, Iio E, et al
    Development of hepatocellular carcinoma from various phases of chronic hepatitis B virus infection.
    PLoS One. 2021;16:e0261878.
    PubMed     Abstract available


  177. CHEN Q, Liu J, He Y, Yang L, et al
    Prevalence of HBsAg among reproductive age couples in Chongqing: A population-based, cross-sectional study.
    PLoS One. 2021;16:e0260028.
    PubMed     Abstract available


  178. AZIT NA, Sahran S, Voon Meng L, Subramaniam M, et al
    Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country.
    PLoS One. 2021;16:e0260675.
    PubMed     Abstract available


  179. NOUANTHONG P, Hefele L, Keokhamphue J, Sorrasin V, et al
    Analyses of blood donor samples from eight provinces in Lao PDR suggest considerable variation concerning HBV exposure and carriage.
    PLoS One. 2021;16:e0259814.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: